• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与乳腺癌患者三级淋巴结构相关的基因组特性和临床结局。

Genomic properties and clinical outcomes associated with tertiary lymphoid structures in patients with breast cancer.

机构信息

Department of Oncology, the First Affiliated Hospital of Zhengzhou University, No.1 Eastern Jianshe Road, Zhengzhou, 450052, Henan, People's Republic of China.

出版信息

Sci Rep. 2023 Aug 19;13(1):13542. doi: 10.1038/s41598-023-40042-7.

DOI:10.1038/s41598-023-40042-7
PMID:37598257
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10439954/
Abstract

Tertiary lymphoid structures (TLSs) play a crucial role in determining prognosis and response to immunotherapy in several solid malignancies. Nevertheless, the effect of TLS-associated gene signature based on The Cancer Genome Atlas (TCGA) cohort in patients with breast cancer (BRCA) remains controversial. Based on TCGA-BRCA dataset (n = 866), 9-gene was identified to construct an TLS signature and further analyzed its prognostic value. Then, we explored the relationship of this TLS signature with molecular subtype, immune microenvironment, tumor mutational burden (TMB). High-TLS signature patients had a better overall survival (OS) than low-TLS signature patients, consistent with the results in the METABRIC cohort. Multivariate analysis revealed that TLS signature remained an independent prognostic indicator for OS. In addition, we established a nomogram with the integration of TLS signature and other independent variables to predict individual risk of death. The comprehensive results showed that patients with high TLS signature benefit from immunotherapy; the signature was also correlated with inhibition of cell proliferation pathways, low TP53 mutation rate, high infiltration of B cells, CD8 + T cells, CD4 + T cells, and M1 macrophages. Therefore, TLS signature is a promising biomarker to distinguish the prognosis and immune microenvironment in BRCA.

摘要

三级淋巴结构 (TLSs) 在几种实体恶性肿瘤中对预后和免疫治疗反应的判断起着至关重要的作用。然而,基于癌症基因组图谱 (TCGA) 队列的 TLS 相关基因特征在乳腺癌 (BRCA) 患者中的作用仍存在争议。基于 TCGA-BRCA 数据集 (n=866),确定了 9 个基因来构建 TLS 特征,并进一步分析其预后价值。然后,我们探讨了该 TLS 特征与分子亚型、免疫微环境、肿瘤突变负荷 (TMB) 的关系。高-TLS 特征患者的总生存期 (OS) 优于低-TLS 特征患者,与 METABRIC 队列的结果一致。多变量分析显示,TLS 特征仍然是 OS 的独立预后指标。此外,我们建立了一个包含 TLS 特征和其他独立变量的列线图,以预测个体死亡风险。综合结果表明,高 TLS 特征的患者受益于免疫治疗;该特征与抑制细胞增殖途径、低 TP53 突变率、B 细胞、CD8+T 细胞、CD4+T 细胞和 M1 巨噬细胞浸润有关。因此,TLS 特征是区分 BRCA 患者预后和免疫微环境的有前途的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/2ffe72ebca23/41598_2023_40042_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/939d95a61700/41598_2023_40042_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/6d9e7ff30717/41598_2023_40042_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/c0a2f2beb215/41598_2023_40042_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/fceae2d8b68a/41598_2023_40042_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/487cdf694085/41598_2023_40042_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/2ffe72ebca23/41598_2023_40042_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/939d95a61700/41598_2023_40042_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/6d9e7ff30717/41598_2023_40042_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/c0a2f2beb215/41598_2023_40042_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/fceae2d8b68a/41598_2023_40042_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/487cdf694085/41598_2023_40042_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f62c/10439954/2ffe72ebca23/41598_2023_40042_Fig6_HTML.jpg

相似文献

1
Genomic properties and clinical outcomes associated with tertiary lymphoid structures in patients with breast cancer.与乳腺癌患者三级淋巴结构相关的基因组特性和临床结局。
Sci Rep. 2023 Aug 19;13(1):13542. doi: 10.1038/s41598-023-40042-7.
2
The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.三阴性淋巴结构的存在为乳腺癌患者的临床病理特征和预后提供了新的见解。
Front Immunol. 2022 May 19;13:868155. doi: 10.3389/fimmu.2022.868155. eCollection 2022.
3
Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.三级淋巴结构模式有助于识别膀胱癌肿瘤微环境浸润和选择治疗药物。
Front Immunol. 2022 Nov 7;13:1049884. doi: 10.3389/fimmu.2022.1049884. eCollection 2022.
4
Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.食管癌患者三级淋巴结构与免疫微环境的综合分析。
Tumori. 2023 Oct;109(5):466-480. doi: 10.1177/03008916231176857. Epub 2023 May 30.
5
A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.一种12种趋化因子基因特征与增强的免疫图谱评分相关,并且与精准免疫治疗相关。
Med Oncol. 2022 Jan 29;39(4):43. doi: 10.1007/s12032-021-01635-2.
6
Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.泛癌症分析与肿瘤三级淋巴结构相关的基因组特征和临床结局。
Sci Rep. 2020 Dec 9;10(1):21530. doi: 10.1038/s41598-020-78560-3.
7
Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.肿瘤内三级淋巴结构可提高头颈部鳞状细胞癌患者的生存率和免疫治疗反应。
Cancer Immunol Immunother. 2023 Jun;72(6):1505-1521. doi: 10.1007/s00262-022-03310-5. Epub 2022 Dec 8.
8
Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.HER2 阳性和阴性乳腺癌中独特的三级淋巴结构关联及其预后相关性。
Oncologist. 2017 Nov;22(11):1316-1324. doi: 10.1634/theoncologist.2017-0029. Epub 2017 Jul 12.
9
Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma.肺腺癌患者三级淋巴结构基因特征的预后意义
Front Oncol. 2021 Jul 26;11:693234. doi: 10.3389/fonc.2021.693234. eCollection 2021.
10
Tertiary Lymphoid Structures Gene Signature Predicts Prognosis and Immune Infiltration Analysis in Head and Neck Squamous Cell Carcinoma.三级淋巴结构基因特征预测头颈部鳞状细胞癌的预后及免疫浸润分析
Curr Genomics. 2024 Apr 8;25(2):88-104. doi: 10.2174/0113892029278082240118053857.

引用本文的文献

1
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.肉瘤中高转座元件表达与免疫浸润增加及包括免疫治疗后在内的预后改善相关。
J Immunother Cancer. 2025 Sep 5;13(9):e012357. doi: 10.1136/jitc-2025-012357.
2
Machine learning model for predicting tertiary lymphoid structures and treatment response in triple-negative breast cancer.用于预测三阴性乳腺癌中三级淋巴结构和治疗反应的机器学习模型
NPJ Precis Oncol. 2025 Jul 1;9(1):216. doi: 10.1038/s41698-025-01012-6.
3
Immune microenvironment and molecular mechanisms in endometrial cancer: implications for resistance and innovative treatments.

本文引用的文献

1
KEGG for taxonomy-based analysis of pathways and genomes.KEGG 用于基于分类的途径和基因组分析。
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. doi: 10.1093/nar/gkac963.
2
The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.三阴性淋巴结构的存在为乳腺癌患者的临床病理特征和预后提供了新的见解。
Front Immunol. 2022 May 19;13:868155. doi: 10.3389/fimmu.2022.868155. eCollection 2022.
3
Cancer statistics, 2022.癌症统计数据,2022 年。
子宫内膜癌中的免疫微环境和分子机制:对耐药性及创新治疗的启示
Discov Oncol. 2025 Apr 16;16(1):532. doi: 10.1007/s12672-025-02169-z.
4
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.疾病中的三级淋巴结构:免疫机制与治疗进展。
Signal Transduct Target Ther. 2024 Aug 28;9(1):225. doi: 10.1038/s41392-024-01947-5.
5
Exploring vasculogenesis in the normal human kidney and clear cell renal cell carcinoma: insights from development to tumor progression and biomarkers for therapy response.探索正常人类肾脏和透明细胞肾细胞癌中的血管生成:从发育到肿瘤进展的见解以及治疗反应的生物标志物
Front Oncol. 2024 Apr 30;14:1375190. doi: 10.3389/fonc.2024.1375190. eCollection 2024.
6
Tertiary lymphoid structures associated with enhanced anti-tumor immunity and favorable prognosis in cervical squamous carcinoma.与宫颈鳞状细胞癌中增强的抗肿瘤免疫和良好预后相关的三级淋巴结构。
Aging (Albany NY). 2024 Apr 17;16(8):6898-6920. doi: 10.18632/aging.205733.
7
Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.三级淋巴结构异质性决定肿瘤免疫和临床应用前景。
Mol Cancer. 2024 Apr 6;23(1):75. doi: 10.1186/s12943-024-01980-6.
8
Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications.癌症中的三级淋巴结构:免疫机制及临床意义
MedComm (2020). 2024 Mar 11;5(3):e489. doi: 10.1002/mco2.489. eCollection 2024 Mar.
9
The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review.三级淋巴结构在乳腺癌中的新兴作用:一篇综述
Cancers (Basel). 2024 Jan 17;16(2):396. doi: 10.3390/cancers16020396.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
4
Tertiary lymphoid structures in cancer.癌症中的三级淋巴结构。
Science. 2022 Jan 7;375(6576):eabf9419. doi: 10.1126/science.abf9419.
5
Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer.肠道菌群特异性滤泡辅助 T 细胞促进结直肠癌三级淋巴结构和抗肿瘤免疫
Immunity. 2021 Dec 14;54(12):2812-2824.e4. doi: 10.1016/j.immuni.2021.11.003. Epub 2021 Dec 2.
6
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.乳腺癌免疫治疗的生物标志物:PD-L1、TILs 及其他。
Expert Opin Investig Drugs. 2022 Jun;31(6):549-555. doi: 10.1080/13543784.2022.2008354. Epub 2021 Nov 25.
7
Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis.三级淋巴结构对乳腺癌预后的影响:一项系统评价与荟萃分析
Cancer Cell Int. 2021 Oct 15;21(1):536. doi: 10.1186/s12935-021-02242-x.
8
Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma.肺腺癌患者三级淋巴结构基因特征的预后意义
Front Oncol. 2021 Jul 26;11:693234. doi: 10.3389/fonc.2021.693234. eCollection 2021.
9
Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells.淋巴结与乳腺癌之间的免疫串扰,重点关注B细胞。
Front Mol Biosci. 2021 May 28;8:673051. doi: 10.3389/fmolb.2021.673051. eCollection 2021.
10
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.高肿瘤突变负担未能预测所有癌症类型的免疫检查点阻断反应。
Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15.